| |
American Company Spotlight

|
Cellceutix Corp. Website:
Click Here |
Information As Of
September
30,
2009 |
| Exchange:
OTCBB |
Market Cap:
36.7
Million |
| Outstanding Shares:
91.8
Million |
52 Low / High:
$0.15 / $1.00 |
|
Price September
30, 2009:
$0.40 |
CTIX Recent Stock Quote and News:
Click Here |
"In
in-vivo testing Kevetrin continues to demonstrate consistent
success in fighting drug resistant cancers, the leading cause
of chemotherapy failure" said Mr. George Evans, CEO of the
Company. Mr. Evans continued: “We are optimistic that Kevetrin
will continue to progress on the developmental pathway as a
treatment for these very difficult cancers."
Overview
Cellceutix Pharmaceuticals, Inc. is an emerging bio-pharmaceutical company in
the business of developing small molecule therapies in areas of unmet medical
need. The Company's primary efforts are in cancer and
inflammatory disease. What differentiates this company from others involved in
cancer drug development is their lead product, Kevetrin, which has been shown in
cell and animal models to be highly effective in treating drug-resistant
cancers.
The Company has recently announced some exciting
results in animal models of multi-drug resistant lung and
breast cancer. Cellceutix is located outside of
Boston, Massachusetts. The senior management of Cellceutix is composed of people
with long experience in researching, developing and marketing innovative
pharmaceutical products.
Investment Highlights
- Exceptional Animal Studies.
Kevetrin has been performing exceptionally during animal
trials. The Company demonstrated success in more than 5,000 small animal
tests, achieving significant delays in tumor growth compared
to controls in breast, prostate and colon cancer tumors.
- Successful In Fighting Drug
Resistant Cancers. One of the main causes of failure in the treatment of cancer
is the development of drug resistance by the cancer cells.
Kevetrin has been studied against several drug-resistant
cancer cell lines.
- Patent Protection. The Company
announced in May of 2009, that
it had filed a U.S. patent
application covering pharmaceutical formulations of a
compound referred to as Kevetrin and many novel compounds
having similar structures to Kevetrin.
- Successes For Various Cancers.
The Company further proved the benefits of Kevetrin when
they announced that they had successfully completed animal
model tests on a taxane-resistant, estrogen
receptor-negative breast cancer human cell line,
MDA-MB-435s, using its proprietary pharmaceutical compound
Kevetrin™. Tumor volume was reduced by 74% and tumor growth
was delayed by more than 62% compared to controls. In
addition, both the tumor volume reduction and the tumor
growth delay were greater with Kevetrin than with paclitaxel
(Taxol) (p<0.01) or with cisplatin (p<0.01).
- Exceptional Management Experience.
Experience at the top is key for medical Companies, and
Cellceutix's CEO, George Evans has more than 25 years
experience in the Pharmaceutical industry. He worked in a
number of positions for Pfizer Inc., one of the largest
pharmaceutical giants in the world. During his time at
Pfizer Mr. Evans gained experience in all aspects of the
pharmaceutical business, from early stage research to
end-of-life-cycle strategies. Mr. Evans also played a key
part in negotiating several major transactions for Pfizer.
Dr. Krishna Menon, President, has more than 35 years in drug
development for academia and industry. Menon was tapped
Group Leader, Cancer In Vivo Research and Clinical
Development, for Eli Lilly (1995-2001). Lastly, Mr. Ehrlich,
CFO, was a founder of Nanoviricides, Inc. (OTCBB:NNVC).
- Competitive Advantages.
Cellceutix owns the patent and rights to a cancer drug that
has performed better in animal tests than the current
standards of treatment.
- Depth of Product Pipeline.
Cellceutix has six additional drugs against a number of
human diseases. The current portfolio of drugs in
pre-clinical development, besides Kevetrin, include another
anti-cancer agent, (KM362); one candidate targeting
rheumatoid arthritis (KM277); a small molecule compound with
an indication of osteo-arthritis/asthma (KM278); a small
molecule compound with an indication of neurological
disorders for the treatment of Multiple Sclerosis, Lou
Gherig Disease, and/or Parkinson's Disease (KM-3174); a
small molecule compound for the treatment of Psoriasis
(KM133); and a small molecule compound to treat hypertensive
emergency a serious condition affecting over 500,000
Americans per year (KM732).
Profile
Cellceutix is an emerging
bio-pharmaceutical company in the business of developing
small-molecule therapies in areas of unmet medical needs. It
owns the rights to seven drug compounds, including Kevetrin,
which it is developing as a treatment for certain cancers, and
KM-133, which it is developing for psoriasis.
Kevetrin, the Company's lead
product candidate, is a small molecule compound proprietary to
the Company. Its structure is distinct from other anti-cancer
agents currently on the market. Kevetrin was discovered by the
Company's founder, Dr. Krishna Menon, and has been studied
extensively (in vitro and in vivo) demonstrating potent
anti-cancer activity against various cancer cell lines.
Kevetrin's recent success in a series of animal model
experiments with drug-resistant cancer cell lines, has
galvanized the Company to focus on Kevetrin's development
potential in this area.
One of the main causes of failure in the treatment of cancer
is the development of drug resistance by the cancer cells.
Kevetrin has been studied against several drug-resistant
cancer cell lines.
The Company announced
in May of 2009, that it had
filed a U.S. patent application covering pharmaceutical
formulations of a compound referred to as Kevetrin and many
novel compounds having similar structures to Kevetrin. These
structures cover a large number of compounds that Cellceutix
can look at as possible drug development candidates. The
application covers the use of Kevetrin and the other compounds
in various areas, including cancers. Cellceutix plans to file
in other countries within a year of the U.S. filing.
The compounds covered by this patent application are
structurally very different from anti-cancer agents currently
on the market. It took the Company
longer than expected to file this patent application due to
the additional compounds that presented themselves as Kevetrin
related structures. The result is a patent with new and
expanded claims that will provide a strong intellectual
property base for Kevetrin and a large portfolio of possible
compounds for future development.
Kevetrin has been performing
exceptionally during animal trials. The Company demonstrated success in more than 5,000 small animal
tests, achieving significant delays in tumor growth compared
to controls in breast, prostate and colon cancer tumors.
The Company further proved the benefits
of Kevetrin when they announced that they had successfully
completed animal model tests on a taxane-resistant, estrogen
receptor-negative breast cancer human cell line, MDA-MB-435s,
using its proprietary pharmaceutical compound Kevetrin™. Tumor
volume was reduced by 74% and tumor growth was delayed by more
than 62% compared to controls. In addition, both the tumor
volume reduction and the tumor growth delay were greater with
Kevetrin than with paclitaxel (Taxol) (p<0.01) or with
cisplatin (p<0.01). The experiment was repeated in order to
increase the level of confidence in the results, though
cisplatin was not included in the repeat experiment. The
results in the repeated experiment were similar to that in the
initial test.
"In in-vivo testing Kevetrin continues to demonstrate
consistent success in fighting drug resistant cancers, the
leading cause of chemotherapy failure" said Mr. George Evans,
CEO of the Company. Mr. Evans continued: “We are optimistic
that Kevetrin will continue to progress on the developmental
pathway as a treatment for these very difficult cancers.”
This is very significant news, as it not only shows that
Kevetrin is beneficial in various types of cancers, but also
that it has been studied against several drug-resistant
cancer cell lines. One of the main
causes of failure in the treatment of cancer is the
development of drug resistance by the cancer cells.
Since Kevetrin's structure is distinct from other
anti-cancer agents currently on the market,
in laboratory tests, it has been able
to overcome that major hurdle.
Experience at the top is key for medical
Companies, and Cellceutix has a CEO that has more than 25
years experience in the Pharmaceutical industry. He worked in
a number of positions for Pfizer Inc., one of the largest
pharmaceutical giants in the world. During his time at
Pfizer Mr. Evans gained experience in all aspects of the
pharmaceutical business, from early stage research to
end-of-life-cycle strategies. Mr. Evans also played a key part
in negotiating several major transactions for Pfizer.
To read the full bio on the the full managment team, scroll
lower to the management section of this profile.
In the above press release, the Company
compared their results with results for Taxol and Cisplatin.
Taxol is made and marketed by Bristol-Myers Squibb Company
(NYSE:BMY). The Company is engaged in the discovery,
development, licensing, manufacturing, marketing, distribution
and sale of pharmaceutical and nutritional products.
Bristol-Myers is a Fortune 500 Company (#129 in 2007 list)
with over 35,000 employees worldwide.
Cisplatin, on the other hand, is a
chemotherapy drug which is used to treat cancers including:
sarcoma, small cell lung cancer, germ cell tumors, lymphoma,
and ovarian cancer. Cisplatin is off-patent. That means no
company has the exclusive right to its manufacture and any
credible drug company can make it (subject to
government-approved safety regulations.) Bristol-Myers Squibb
settled with the Federal Trade Commission in 2003 over charges
it engaged in anti-competitive practices to keep the price of
cisplatin high.
Having a junior medical Company that
owns the patent and rights to a cancer drug that has performed
better in animal tests than a Fortune 500 pharmaceutical
Company's Cancer drug, should in its own right, raise some
eyebrows. Medical buyouts are not uncommon, in fact, a major
buyout occurred just last year involving cancer drugs.
In October of 2008, ImClone Systems Inc.
received a takeover offer from a large pharmaceutical company,
Eli Lilly, valued at over $6 Billion. The cancer drug ImClone
is known for, is Erbitux--a product that it markets in
partnership with Bristol. ImClone also has a promising cancer
drug candidate that's either a follow-up to or potential
competitor for Erbitux.
With Cancer still one of the deadliest
worldwide diseases, plenty of money and resources are given to
try and provide treatments and cures. A small cap medical
Company that holds lots of promise, and will no doubt capture
the attention of many large pharmaceutical Companies is
Cellceutix Corp. (OTCBB:CTIX). The positive results of their
lead cancer drug, Kevetrin, along with their very experienced
management team, were more than enough reason for
AllPennyStocks.com to take a closer look at the Company and
spotlight it to their investors.
The stock has been on a bit of a run-up
over the last month as investors find out about this emerging
medical Company. With tonight's important press release,
investors are encouraged to watch the trading in this Company
over the next week as Cellceutix continues to turn heads with
its impressive lead cancer drug.
Kevetrin -
Lead Product
Excellent results in animal model experiments in
drug-resistant cancers
Kevetrin, the Company's lead
product candidate, is a small molecule compound proprietary
to the Company. Its structure is distinct from other
anti-cancer agents currently on the market. Kevetrin was
discovered by the Company's founder, Dr. Krishna Menon, and
has been studied extensively (in vitro and in vivo)
demonstrating potent anti-cancer activity against various
cancer cell lines. Kevetrin's recent success in a series of
animal model experiments with drug-resistant cancer cell
lines, has galvanized the Company to focus on Kevetrin's
development potential in this area. Kevetrin's primary
mechanism of action is as an AKT inhibitor but it also acts
as an alkylating agent and LTB4 inhibitor with
anti-angiogenic properties.
Some highlights of the studies conducted to date include:
- Small molecule drug that is structurally different from
anti-cancer agents currently on the market
- Primary mechanism of action is AKT inhibition
- Potent in vitro cytotoxicity against a panel of human
tumor cell lines
- Demonstrated success in more than 5,000 small animal
tests, achieving significant delays in tumor growth compared
to controls in breast, prostate and colon cancer tumors.
- In animal tests of a head and neck cancer cell line,
delay in tumor growth was significantly increased by 14 days
with Kevetrin alone (about the same as with radiation alone)
but when Kevetrin was administered in conjunction with
radiation, tumor growth delay increased by 36 days, more
than two-fold compared to controls
- In small animal tests, Kevetrin was well tolerated.
The Company is now conducting
additional studies to allow them to
request permission from the FDA to
begin studies in humans.
Chemistry
Kevetrin is a small molecule that is different in structure
from all currently marketed cancer drugs. It is water-soluble
and simple to synthesize from commercially available starting
materials. The Company expects
that it will initially be administered as an intravenous (IV)
product.
Patent Protection
Cellceutix filed a patent application covering Kevetrin in
May, 2009. The patent application claims pharmaceutical
formulations of Kevetrin in addition to novel compounds having
similar structures to Kevetrin that may have potential as drug
development candidates. The application also covers the use of
Kevetrin and the other compounds in various disease states,
including cancers. Cellceutix plans to file patent
applications in other countries within a year of the U.S.
filing.
Drug-Resistant Cancer Cell Lines
One of the main causes of failure in the treatment of cancer
is the development of drug resistance by the cancer cells.
Kevetrin has been studied against several drug-resistant
cancer cell lines.
Lung Cancer
Kevetrin has been studied in animal models using a number of
drug-resistant cell lines. Kevetrin was studied in two cell
lines of multi-drug resistant lung cancer. In two studies with
the A549 cell line, Kevetrin showed average tumor growth delay
of 72% and average tumor volume reduction of 81% compared to
controls. Both tumor growth delay and tumor volume reduction
were also significantly greater with Kevetrin than with
paclitaxel (Taxol) (p<0.001).
In two studies with the NCI-H1975 cell line of multi-drug
resistant lung cancer, Kevetrin showed average tumor growth
delay of 149% and tumor volume reduction of 94% compared to
controls. Both tumor growth delay and tumor volume reduction
were greater with Kevetrin than with paclitaxel (p<0.001).
Other Cancer Cell Lines:
Head and Neck Cancer
Kevetrin was studied in multiple experiments alone and in
conjunction with radiation against the SCC-15 cell line of
head and neck cancer. Kevetrin alone showed an average tumor
growth delay of 45% compared to controls, similar to radiation
alone. When administered in conjunction with radiation,
Kevetrin showed an average tumor growth delay of 116%.
Colon Cancer
Kevetrin was studied in two experiments alone and in
combination with 5-FU against the HT-29 cell line of colon
cancer. Kevetrin alone demonstrated average tumor growth delay
of 43% compared to controls. 5-FU alone showed an average
tumor growth delay of 20%. The combination of Kevetrin and
5-FU resulted in an average tumor growth delay of 97%.
Breast Cancer
In a study with the MDA-MB-231 breast cancer cell line,
Kevetrin demonstrated tumor growth delay of 90% compared to
controls.
Prostate Cancer
Kevetrin was studied against the PC-3 cell line of prostate
cancer. In two studies, Kevetrin demonstrated an average tumor
growth delay of 54% compared to controls, while cisplatin
showed and average tumor growth delay of 49%.
Recent News and Press Releases
Cellceutix Meets With One of the World's Largest
Pharmaceutical Companies At Partnering Meeting
GlobeNewswire (Wed, Sep 23)
Cellceutix's Kevetrin(TM) Demonstrates Significant Delay of
Tumor Growth in Drug Resistant Breast Cancer
GlobeNewswire (Mon, Sep 21)
Cellceutix Announces Acquisition of New Compound With High
Blood Pressure Lowering Properties
GlobeNewswire (Tue, Aug 25)
Cellceutix Signs Agreement for Kevetrin(tm) API
GlobeNewswire (Mon, Aug 17)
Cellceutix's Cancer Drug Shows No Significant Indications of
Toxicity
GlobeNewswire (Wed, Jul 22)
Cellceutix Announces Dr. Samuel Danishefsky Joins Its
Scientific Advisory Board
GlobeNewswire (Tue, Jul 14)
Cellceutix Announces Kevetrin(tm) Animal Model Testing Success
Against Multi-Drug Resistant Lung Cancer Cell Lines
GlobeNewswire (Mon, Jul 13)
Cellceutix Announces Dr. Emil Frei to be On Its Scientific
Advisory Board Through June 30, 2010
GlobeNewswire (Tue, Jun 30)
Management
Chief Executive Officer, Chairman of the Board of
Directors- George W. Evans, JD, MBA; George Evans has
more than 25 years experience in the Pharmaceutical industry.
He worked in a number of positions for Pfizer Inc, ending his
career there as General Counsel for Pfizer's worldwide
prescription drug unit, and a member of the unit's leadership
team. During his time at Pfizer Mr. Evans gained experience in
all aspects of the pharmaceutical business, from early stage
research to end-of-life-cycle strategies. Mr. Evans also
played a key part in negotiating several major transactions
for Pfizer. In addition to his direct business experience, Mr.
Evans has a wealth of experience in building and integrating
organizations while maintaining the highest levels of
performance. Mr. Evans was a member of the Editorial Advisory
Board and the Finance Committee of the Food and Drug Law
Institute and a member of the Board of the City Bar Fund. He
is a graduate of Williams College and Columbia University's
Law and Business schools.
President, Chief Scientific Officer, Board of Directors -
Dr. Krishna Menon RCM, PhD, VMD - Dr. Krishna Menon has
more than 35 years in drug development for academia and
industry. Originally trained as a veterinary surgeon, Menon
began his career as Chief Government Veterinarian for a major
Parish in Jamaica. He segued to a three-year stint as Director
of Agriculture for the Cayman Islands, in the British
Caribbean and, in 1982, moved to the Dana Farber Cancer
Research Institute, where he worked under the direction of Dr.
Emil Frei. Two years later, he earned his PhD in Pharmacology
from Harvard University. Menon's PhD work focused on
anti-folate therapy of various cancers. Menon was a Research
Scientist at Dana Farber from 1985 to 1990 and Senior Research
Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals
(Miles Laboratories) from 1991 to 1993. After a year operating
his own veterinary oncology and drug development consultancy
practice, Menon was tapped Group Leader, Cancer In Vivo
Research and Clinical Development, for Eli Lilly (1995-2001),
where he played a key role in lead selection and pre-clinical
development of Gemzar and Alimta which in 2006 had over 2.1
billion dollars ($2,100,000,000) in sales, and is a
co-developer of another seven compounds currently in
late-stage clinical development. In 1999, Lilly honored Menon
with the President's Recognition Award, an award not bestowed
annually but rather on only special occasions.
Chief Financial Officer, Board of Directors- Leo Ehrlich,
CPA Served as Chief Financial Officer (CFO) of
Cellceutix Pharma since inception in June 2007. Following the
acquisition, he was appointed CFO and a director. Mr. Ehrlich was also
founder of Nanoviricides, Inc. (OTCBB:NNVC). That Company
started with limited trading volume and a very small market
cap and has a present market cap of over $100 million dollars. Mr. Ehrlich is a Certified Public Accountant
and received his BBA from Bernard Baruch College of the City
University of New York.
Contact
Cellceutix Corp.
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-633-3623
Fax: 978-921-6564
Email:
info@cellceutix.com
FORWARD LOOKING STATEMENTS
This report includes forward-looking
statements that reflect Cellceutix Corp. current
expectations about its future results, performance,
prospects and opportunities.
Cellceutix Corp. has
tried to identify these forward-looking statements by using
words and phrases such as "may," "will," "expects,"
"anticipates," "believes," "intends," "estimates," "plan,"
"should," "typical," "preliminary," "we are confident" or
similar expressions. These forward-looking statements are
based on information currently available and are subject to
a number of risks, uncertainties and other factors that
could cause Cellceutix Corp.'s actual results,
performance, prospects or opportunities to differ materially
from those expressed in, or implied by, these
forward-looking statements. These risks, uncertainties and
other factors include, without limitation, the Company's
growth expectations and ongoing funding requirements, and
specifically, the Company's growth prospects with scalable
customers, and those outlined above. Other risks include the
Company's limited operating history, the Company's history
of operating losses, consumers' acceptance, the Company's
use of licensed technologies, risk of increased competition,
the potential need for additional financing, the terms and
conditions of any financing that is consummated, the limited
trading market for the Company's securities, the possible
volatility of the Company's stock price, the concentration
of ownership, and the potential fluctuation in the Company's
operating results.
Disclaimer
AllPennyStocks.com feature stock reports
are intended to be stock ideas, NOT recommendations. Please
do your own research before investing. It is crucial that
you at least look at current SEC filings and read the latest
press releases. Information contained in this report was
extracted from current documents filed with the SEC, the
company web site and other publicly available sources deemed
reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document
contains forward-looking statements, particularly as related
to the business plans of the Company, within the meaning of
Section 27A of the Securities Act of 1933 and Sections 21E
of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results
may differ materially from the Company's expectations and
estimates. This is an advertisement for
Cellceutix Corp. The purpose of this advertisement, like any
advertising, is to provide coverage and awareness for the
company. The information provided in this advertisement is
not intended for distribution to, or use by, any person or
entity in any jurisdiction or country where such
distribution or use would be contrary to law or regulation
or which would subject us to any registration requirement
within such jurisdiction or country.
© 1999-2009 AllPennyStocks.com. All rights
reserved. AllPennyStocks.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves
out to be. All materials presented on our web site and
individual reports released to the public through this web
site, e-mail or any other means of transmission are not to
be regarded as investment advice and are only for
informative purposes. Before making a purchase or sale of
any securities featured on our web site or mentioned in our
reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to
be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to
profile involve a degree of investment risk and volatility.
Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their
investment if they decide to make a purchase in any of our
profiled companies. Past performance of our profiled stocks
is not indicative of future results. The accuracy or
completeness of the information on our web site or within
our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are
expressed as of the date the profile is posted on site and
are subject to change without notice. No investor should
assume that reliance on the views, opinions or
recommendations contained herein will produce profitable
results. AllPennyStocks.com may hold positions in securities
mentioned herein, and may make purchases or sales in such
securities featured on our web site or within our reports.
In order to be in full compliance with the Securities Act of
1933, Section 17(b), AllPennyStocks.com will disclose in
it's disclaimer, what, if any compensation was received for
our efforts in researching, presenting and disseminating
this information to our subscriber database and featuring
the report on the AllPennyStocks.com web site.
AllPennyStocks.com has been compensated
ten thousand dollars by
the Company for its efforts in presenting the
CTIX profile
on its web site and distributing it to its database of
subscribers as well as other services. AllPennyStocks.com
may decide to purchase or sell shares on a voluntary basis
in the open market before, during or after the profiling
period of this report. As of the profile date, no shares
have been sold. Information presented on our web site and
within our reports contain "forward looking statements"
within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934.
Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans,
projections, objectives, goals, assumptions or future events
or performance are not statements of historical fact and may
be "forward looking statements." Forward looking statements
are based on expectations, estimates and projections at the
time the statements are made that involve a number of risks
and uncertainties which could cause actual results or events
to differ materially from those presently anticipated.
Forward looking statements in this action may be identified
through the use of words such as “expects’”, “will,”
“anticipates,” “estimates, “believes,” or that by statements
indicating certain actions “may,” “could,” or “might” occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO
THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES
MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE
AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest
carefully and read the investor information available at the
web sites of the Securities and Exchange Commission (SEC)
at:
http://www.sec.gov and/or the National Association of
Securities Dealers (NASD) at:
http://www.nasd.com. Readers can review all public
filings by companies at the SEC's EDGAR page. The NASD has
published information on how to invest carefully at its web
site.
|
|